EMAIL THIS PAGE TO A FRIEND

Life sciences

Electro-acupuncture up-regulates astrocytic MCT1 expression to improve neurological deficit in middle cerebral artery occlusion rats.


PMID 26037401

Abstract

Cerebral ischemia is one of the common diseases treated by electro-acupuncture (EA). Although the clinical efficacy has been widely affirmed, the mechanisms of action leading to the health benefits are not understood. In this study, the role of EA in modulating the lactate energy metabolism and lactate transportation was explored on the middle cerebral artery occlusion (MCAO) ischemic rat model. Repeated EA treatments once daily for 7 days were applied to the MCAO rats and neurological function evaluation was performed. Brain tissues were harvested for lactate concentration examination, immunohistochemical staining, Western blot and qRT-PCR analyses for the expressions of lactate transporter (monocarboxylate transporter 1, MCT1) and glial fibrillary acidic protein (GFAP). The animal behavioral tests showed that the 7-day EA treatments significantly promoted the recovery of neurological deficits in the MCAO rats, which correlated with the enhanced lactate energy metabolism in the ischemic brain. In the cortical ischemic area of the MCAO rats, EA treatments led to the activation of astrocytes, and induced a further increase of lactate transporter (monocarboxylate transporter 1, MCT1) expression in astrocytes at both protein and mRNA levels. Our results suggest that the EA treatments activated lactate metabolism in the resident astrocytes around the ischemic area and up-regulated the expression of MCT1 in these astrocytes which facilitated the transfer of intracellular lactate to extracellular domain to be utilized by injured neurons to improve the neurological deficit.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2501828
Anti-CMA1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2700037
Anti-CMA1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA052634 Anti-CMA1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2107486
Anti-CMA1 antibody produced in rabbit, affinity isolated antibody
SAB1306015
ANTI-MCT-1(N-TERMINAL) antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB2502128
Anti-MCTS1 (N-terminal) antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2701331
Anti-MCTS1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2103663
Anti-MCTS1, (N-terminal) antibody produced in rabbit, affinity isolated antibody, lyophilized powder
SAB1406450
Anti-SLC16A1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA003324
Anti-SLC16A1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2105147
Anti-SLC16A1 antibody produced in rabbit, affinity isolated antibody
SAB1411291
Anti-SLC16A1 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1401656
Monoclonal Anti-MCTS1 antibody produced in mouse, clone 1G1-2A2, ascites fluid